Literature DB >> 23296246

Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.

Scott L Friedman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296246     DOI： 10.1038/nrgastro.2012.256

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Our unindicted coconspirators: human metabolism from a microbial perspective.

Authors:  Andrew L Goodman; Jeffrey I Gordon
Journal:  Cell Metab       Date:  2010-08-04       Impact factor: 27.287

3.  Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Authors:  Cynthia D Guy; Ayako Suzuki; Marzena Zdanowicz; Manal F Abdelmalek; James Burchette; Aynur Unalp; Anna Mae Diehl
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

Review 4.  Targeting the Hedgehog signaling pathway for cancer therapy.

Authors:  Yiwei Li; Ma'in Y Maitah; Aamir Ahmad; Dejuan Kong; Bin Bao; Fazlul H Sarkar
Journal:  Expert Opin Ther Targets       Date:  2012-01       Impact factor: 6.902

Review 5.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

6.  Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.

Authors:  Valerio Nobili; Guido Carpino; Anna Alisi; Antonio Franchitto; Gianfranco Alpini; Rita De Vito; Paolo Onori; Domenico Alvaro; Eugenio Gaudio
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Angelo H Paredes; Dawn M Torres; Stephen A Harrison
Journal:  Clin Liver Dis       Date:  2012-05       Impact factor: 6.126

8.  Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice.

Authors:  Kouichi Miura; Ling Yang; Nico van Rooijen; David A Brenner; Hirohide Ohnishi; Ekihiro Seki
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962
  9 in total
  29 in total

1.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.

Authors:  Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner
Journal:  Gastroenterology       Date:  2015-08-20       Impact factor: 22.682

Review 2.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 3.  PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.

Authors:  Li-Zhen Chen; Yong-Ning Xin; Ning Geng; Man Jiang; Ding-Ding Zhang; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 4.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

Review 5.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

6.  Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.

Authors:  D Lee Gorden; David S Myers; Pavlina T Ivanova; Eoin Fahy; Mano R Maurya; Shakti Gupta; Jun Min; Nathanael J Spann; Jeffrey G McDonald; Samuel L Kelly; Jingjing Duan; M Cameron Sullards; Thomas J Leiker; Robert M Barkley; Oswald Quehenberger; Aaron M Armando; Stephen B Milne; Thomas P Mathews; Michelle D Armstrong; Chijun Li; Willie V Melvin; Ronald H Clements; M Kay Washington; Alisha M Mendonsa; Joseph L Witztum; Ziqiang Guan; Christopher K Glass; Robert C Murphy; Edward A Dennis; Alfred H Merrill; David W Russell; Shankar Subramaniam; H Alex Brown
Journal:  J Lipid Res       Date:  2015-01-17       Impact factor: 5.922

7.  PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.

Authors:  Wenfeng Zhang; Yan Liu; Mingbing Wu; Xiwen Zhu; Tao Wang; Kun He; Peizhi Li; Xiaoling Wu
Journal:  J Physiol Biochem       Date:  2017-09-13       Impact factor: 4.158

Review 8.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 9.  Developmental origins of nonalcoholic fatty liver disease.

Authors:  David E Brumbaugh; Jacob E Friedman
Journal:  Pediatr Res       Date:  2013-11-05       Impact factor: 3.756

Review 10.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.